Back to all studies
❤️
Phase 2
Cardiology
in-person
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Sponsored by Regeneron Pharmaceuticals
Compensation
$500–$2,500
Duration
3 months
Location
Colorado
About this study
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against R…
Who can participate
- • Adults aged 18–99
- • All genders welcome
- • Diagnosed with or experiencing pulmonary arterial hypertension (pah)
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.